BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING CD123 AND CD3, AND USES THEROF

The present invention is directed to sequence-optimized CD123 x CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.

Saved in:
Bibliographic Details
Main Authors BONVINI, Ezio, ALDERSON, Ralph Froman, CHICHILI, Gurunadh Reddy, MOORE, Paul A, HUANG, Ling, JOHNSON, Leslie S
Format Patent
LanguageEnglish
French
German
Published 21.04.2021
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention is directed to sequence-optimized CD123 x CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.
Bibliography:Application Number: EP20200206324